SCHEMBL4704308

SCHEMBL4704308

CN1C(=O)C(c2cccc(-c3ccccc3)c2)(C2CCNCC2)N=C1N

nearest known ligand 0.70

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 0.70
BACE2 Q9Y5Z0 9/20 0.69
CTSD P07339 2/20 0.63
APP P05067 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5144775 0.99 BACE1 (0.69) BACE1BACE2CTSDAPP
SCHEMBL5146663 0.90 BACE1 (0.77) BACE1BACE2CTSDAPP
SCHEMBL4707325 0.83 BACE1 (0.65) BACE1BACE2CTSDAPP
SCHEMBL4705972 0.83 BACE1 (0.64) BACE1BACE2CTSDAPP
SCHEMBL14422948 0.82 BACE1 (0.62) BACE1BACE2CTSDAPP
SCHEMBL4706837 0.82 BACE1 (0.63) BACE1BACE2CTSDAPP
SCHEMBL27727857 0.82 BACE1 (0.63) BACE1BACE2CTSDAPP
Hydrochloric Acid SCHEMBL5166284 0.81 BACE1 (0.61) BACE1BACE2CTSDAPP
SCHEMBL5148226 0.81 BACE1 (0.64) BACE1BACE2CTSDAPP
SCHEMBL4706115 0.81 BACE1 (0.62) BACE1BACE2CTSDAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101360737-A 2-amino-5-piperidinylimidazolone compounds and their use for beta secretase modulation WYETH CORP (US) 2009-02-04 CN disclosed
EP-1966185-A2 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION Wyeth a Corporation of the State of Delaware (US) 2008-09-10 EP disclosed
US-20070191431-A1 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation WYETH (US) 2007-08-16 US disclosed
US-20070191431-A1 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation WYETH (US) 2007-08-16 US disclosed
US-20070191431-A1 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation WYETH (US) 2007-08-16 US disclosed
WO-2007078813-A2 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION WYETH (US) 2007-07-12 WO disclosed
WO-2007078813-A2 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION WYETH (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191431-A1 2-Amino-5-piperidinylimidazolone compounds and use thereof for beta-secretase modulation BACE1, BACE2, PSEN1 BACE1 1/4885BACE2 2/4885CTSD 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.